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Inherited hyperbilirubinemias are a group of metabolic disorders, characterized by increased 
levels of total serum bilirubin or its conjugated fraction. Most of these hyperbilirubinemias are 
inherited autosomal recessively and are manifested in young age. Increased bilirubin reflects the 
genetic disturbances in one of the enzymes of heme degradation pathway, the defect of bilirubin 
conjugation (UGT1A1 gene) or its transport (ABCC2, OATP1B1, OATP1B3). All of these proteins 
are involved not only in elimination of bilirubin, but various substrates; therefore the performed 
studies have a great pharmacogenomics impact. We have studied the molecular pathology of 
hereditary hyperbilirubinemias in Caucasian and Roma population and to compare the clinical 
and biochemical results with the molecular genetic data. We described the impact of compound 
defect of c.-3279T>G and g.175492_175493insTA on total serum bilirubin and calculated the 
linkage disequlibrium of these two variants in promoter region of UGT1A1 gene. We also verified, 
that the population distribution of both variants is in concordance with the literature.  
In our second study, we have described the rare conjugated hyperbilirubinemia Dubin-Johnson 
type among 7 Roma families. We have found a novel variant NG_011798.1:c.[1013_1014delTG] 
together with the dual genetic defect – a combination of Dubin-Johnson and Gilbert`s syndrome. 
We have described a founder effect of the mutation in ABCC2 and found a common haplotype of 
86 bp encompassing the gene. We have also characterized the excretion of coproporphyrin 
isomers in patients with DJS and compared it with those with dual hereditary jaundice.  
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Dědičné hyperbilirubinémie představují skupinu metabolických onemocnění, charakterizovaných 
zvýšenou hladinu celkového bilirubinu nebo jeho konjugované frakce v séru. Většina těchto 
hyperbilirubinémií je děděná autosomálně recesivně a jsou manifestovány zejména v mladém 
věku. Zvýšený bilirubin je zapříčiněn poruchami v některém z enzymů metabolické dráhy hemové 
degradace, ať už jeho konjugace (UGT1A1) nebo transportu (ABCC2, OATP1B1, OATP1B3). 
Všechny proteinové produkty těchto genů se účastní nejen eliminace bilirubinu, ale take různých 
dalších substrátů. Studie těchto protein mají tedy široký farmakogenomický vliv. Tato studie 
popisuje molekulární podstatu dědičných hyperbilirubinémií u kavkazské a romské populace, 
srovnává klinická a biochemická data s výsledky molekulární genetiky. Dále popisujeme vliv 
současného výskytu variant c.-3279T>G a g.175492_175493insTA na hladinu celkového  sérového 
bilirubinu . Stanovili jsme vazebnou nerovnováhu obou variant lokalizovaných v promotorové 
oblasti genu UGT1A1. Zároveň jsme ověřili konzistenci populačních dat s výsledky v literature.  
Ve druhé studie jsme popsali vzácnou konjugovanou hyperbilirubinémii Dubin-Johnsonova typu 
u 7 romských rodin. Našli jsme novou variantu v ABCC2 genu NG_011798.1:c.[1013_1014delTG] 
a take dvojitý genetický defect – kombinaci Dubin-Johnsonova a Gilbertova szndromu. Popsali 
jsme novou mutaci v genu ABCC2 a našli společný haplotyp o velikosti 86 bp v blízkosti genu.  
Dále jsme charakterizovali exkreci izomerů koproporpfyrinu a srovnali data pacientů s DJS a 
dvojitou hereditární žloutenkou.  
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ABCC2 – gene/protein ABCC2, ABC cassette transporter 2 
bp – base pair 
cBi – conjugated bilirubin 
cMOAT – canalicular multiorganic anion transporter 
CNJ – Crigler-Najjar syndrome 
CO - carbon monoxide 
DJS – Dubin-Johnson syndrome 
GS – Gilbert` s syndrome 
HO – heme oxygenase 
MRP2 – multidrug resistance associate protein 2 
NADPH - nicotin amide dinucleotide phosphate cofactor 
OR – ODDs ratio 
PBREM – phenobarbital responsive enhancer element 
RS – Rotor syndrome 
Tbi – total serum bilirubin 
































From ancient Greek, a jaundice, a yellowish pigmentation of skin or sclerae, has been observed 
as an unhealthy or diseased condition.  Since that time, humans have come a long way to identify 
its causes and find a desired cure. Depending on the development of investigation techniques, 
various causes of jaundice have been discovered, including those caused by genetic defects. The 
first comment on jaundice was made by the French physician Jean Baptiste Thimotee Baumes 
(Baumes,  1806) in his book Traite de L’amaigrissement des enfans. In 1922, the ages before the 
identifying genes or DNA, Meulegracht hypothesized, that some of the hyperbilirubinemias might 
be inherited (Meulengracht, 1992). 
Bilirubin and inherited hyperbilirubinemias became a popular topic. The key molecule of UDP 
glucuronosyl-tranferase was experimentally proven to play a significant role in inherited 
hyperbilirubinemia, yet not in all of them. Later, the scientific world was shaken by the exciting 
epoch of molecular biology and this progress added a new layer in the understanding of 
hyperbilirubinemias. The milestone was firmly set by the revelation of UGT1A1 gene and its 
defects, responsible for the majority of inherited defects of bilirubin metabolism. The key 
offender was identified, but still many pieces were left to complete the puzzle and the causes of 
conjugated hyperbilirubinemias still remained unknown. The expectation of genetic defects in 
bilirubin transporter ABCC2 was confirmed in 1998 by the work of Wada et al (Wada et al, 1998). 
The final puzzle piece remained. 
Identification of the last inherited hyperbilirubinemia, Rotor syndrome, examined and challenged 
researchers for several years. Finally, in 2012, a digenic disturbance of bilirubin transport was 
uncovered by team of Netherland and Czech authors (Steeg et al, 2012). 
Therapy of jaundice wasn`t quite following the path of discoveries, and as in most of the findings, 
serendipity played a significant role. In the mid 1950`s, a nurse from England noticed that 
newborns exposed to sunlight by windows showed less jaundice and lower bilirubin levels than 
others. This observation led to the development of the biggest tool of jaundice treatment up to 
today – a phototherapy. 
12 
 
Today`s knowledge of inherited hyperbilirubinemia answered many questions and saved many 
lives. And as in almost every field of science, more questions were put on the table. 
I.II. BILIRUBIN 
Heme is the essential compound of the eukaryotic cells. As a part of hemoproteins, it is involved 
in cellular respiration, oxidative responses and signaling. On the other side, its excessive amount 
is toxic, therefore intracellular heme pool and heme catabolism is tightly regulated. Heme is 
degraded by heme oxygenase and the resulting product of heme degradation is biliverdin Ixα, 
which is further transformed to bilirubin Ixα, carbon monoxide and iron. In humans, a major 
source of bilirubin is heme, derived from hemoglobin released from senescent erythrocytes           
(~ 80%) (London et al, 1950). Other sources of heme are hemoproteins such as peroxidases, 
catalases; or myoglobin. Erythrocytes lifespan is about 120 days and a daily production of 
bilirubin is 250 – 400 mg. Even though every eukaryotic cell is able to produce bilirubin, the 
majority of heme degradation occurs in the reticuloendothelial system of spleen and liver. 
I.II.I. Biochemistry of heme degradation 
1. Heme oxidation 
Once released from the hemoglobin molecule, heme is available for the heme degradation. The 
breakdown reaction starts with the oxidative cleavage of the α-methylene bridge of heme by the 
enzyme heme oxygenase (HO) (Tenhunen 1968). As a product, equimolar amounts of CO, 
biliverdin and iron is made (Tenhunen et al., 1968). Reaction needs reduced form of nicotin amide 
dinucleotide phosphate cofactor (NADPH) and 3 molecules of oxygen.  
The reaction occurs in three mono-oxygenation cycles. In each of the cycle iron binds oxygen 
which accepts the second electron from NADPH (Yoshida et al). Such an activated oxygen 
complex cleaves the heme ring. In the first cycle the hydroxyl-heme is formed, in the second  
verdoheme is formed, and in the third reaction ferribiliverdin IXa is formed. Additional reduction 
of ferribiliverdin by NADPH is followed by release of ferrous iron from biliverdin (Yoshida 1978).  
Heme b + 3O2 + 3½NADPH + 3½H+ → biliverdin + Fe2+ + CO + 3½NADP+ + 3H2O 
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Heme oxygenase is a ubiquitous highly inducible enzyme from a family of heat shock proteins. 
There are three isoforms of the enzyme (HO-1, HO-2, HO3). The protein is anchored in the 
membrane of the endoplasmic reticulum, a place of the heme oxidation. It is also present  in the 
other membrane compartments. The oxidation of heme by HO is very important as it is the only 
rate limiting step in bilirubin formation. Before the oxidation step, it is unclear how the 
hydrophobic molecule of heme is transported from phagosome where it is generated through 
the cytosol up to the endoplasmic reticulum.  
The most important in heme degradation is the inducible form of heme oxygenase, HO-1, highly 
expressed in liver cells. HO-1 inducibility is highly responsive to various stimuli, including physical, 
chemical, or biological impacts. Compared to the HO-1, HO-2 expression is constitutive and it is 
limited to certain tissues including testes or neuronal cells. Third isoform HO-3 is not catalytically 
active. In vitro, the HO activity can be induced adding NADH or NADPH. On the other side, HO is 
inhibited by its reaction product – biliverdin. This step is final for heme degradation in reptiles 
and amphibians who are able to excrete biliverdin.  
Aside of the main purpose to create biliverdin and furtherly bilirubin, the reaction of heme 
breakdown has significant effects. Iron cleaved off the heme is toxic for the cell, therefore it has 
to be transported or bound to the protein for its reutilization. CO, the other by-product of heme 
degradation is important on both cellular and tissue levels for its antiinflamatory and 
antiapoptotic effects, and for the regulation of the vascular tone through cGMP or by activating 
MAPK. 
2. Reduction of biliverdin to bilirubin 
The next step of bilirubin formation is the reduction of biliverdin IXa by biliverdin reductase 
(Tenhunen et al, 1970). The reaction requires the presence of NADPH as a cofactor. Biliverdin 
reductase is a cytosolic enzyme of great importance. Next to its ability to convert biliverdin to 
bilirubin, biliverdin reductase is a regulator of insulin/IGF -1/IRK/PI3K/MAPK pathways, 
suggesting that it can be a potential regulator of cell proliferation and growth with the 
implications in a cancer therapy. Another effect of biliverdin reductase is antiinflamatory, 
antiapoptotic and oxidative stress prevention (Kim et al, 2015). However, the step of the 
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reduction of biliverdin to bilirubin is interesting.  The biliverdin itself is water soluble already and 
by the reduction by biliverdin reductase, the product becomes insoluble. The step occurs in the 
cytosol.  
3. Conjugation of bilirubin with glucuronic acid 
Insoluble 4Z, 15Z-bilirubin IXa even when highly antioxidant, is toxic for the cells. Therefore it has 
to be converted to a water soluble product to be easily eliminated. This is mediated by the 
conjugation of bilirubin with glucuronic acid by enzyme UDP- glucuronosyl transferase 1A1, the 
only enzyme catalyzing bilirubin glucuronidation in humans (Blanckaert, Bock).  Reaction results 
in the esterification of carboxyle groups of bilirubin by the glucuronic acid and releasing of 
hydrogen bonds in the molecule. The products are in great majority bilirubin diglucuronides (~ 
80%), also monoglucuronides are formed (Onishi, 1980, Chowdhury 1982). The process occurs in 
endoplasmic reticulum of hepatocytes.  
The role of UGT1A1 is to metabolize not only bilirubin, but a myriad of toxic endogenous 
xenobiotics. UGT1A1 is a member of an extensive UGT family with a large substrate affinity, 
playing the most important role as a phase 2 drug metabolizing enzymes. UGT is present in 
bacteria, plants, animals, as well as in humans. According to a modeled structure, UGT1A1 has a 
deep pocket formed by N-terminal domain next to the donor binding site of the molecule. 
According to the characteristics, the pocket is probably the acceptor binding site of the enzyme 
(Figure 1). The enzymatic activity of UGT1a1 can be stimulated by various chemicals, including 





Figure 1: Molecular docking of bilirubin into the human UGT1A1 protein.  (B) Diagram showing 
positions of the modeled substrates. The UGT1A1 is shown in a ribbon diagram with the secondary 
structure highlighted. The donor UDP glucuronic acid (UDPGA) is shown in a dark blue. The two 
docked conformations of bilirubin are shown as red and green sticks. (C) Diagram showing 
bilirubin (red conformation) docked into the acceptor-binding pocket of UGT1A1. UDPGA (blue) 
and bilirubin (red) are shown as lines. Some residues in the acceptor-binding pocket are labeled 
and shown in cyan. Modified according to Li and Wu 
4. Bilirubin transport 
Bilirubin conjugation with glucuronic acid forming mostly bilirubin diglucuronides makes the 
bilirubin water soluble and accessible for its transport into the bile. In humans, this step is 
mediated by multidrug resistance associated protein 2 (MRP2), an ATP dependent transport 
pump localized at the canalicular membrane of hepatocytes. By MRP2, the bilirubin 
diglucuronide (bilirubin conjugate) is transported from hepatocytes to bile canaliculi and to the 
bile. Mutations in MRP2 cause Dubin Johnson syndrome, the inherited conjugated 




5. Bilirubin catabolism 
Conjugated bilirubin, transported from hepatocytes into the bile, is as a part of bile directed into 
the duodenum and then to large intestine. In a large intestine it is degraded by the bacterial 
enzymes glucuronidases, cleavaging the glucuronide residues and forming colorless 
urobilinogens. Certain amount of bilirubin is excreted by alternative pathway via kidneys (Watson 
1969, Vitek et al 2005, Vitek et al 2006, Chowdhury et al 1983).  
I.II.II. Bilirubin structure 
Bilirubin was a compound of a great interest in the first half of the 20th century and the most 
significant findings were made in the period of World War II. Originally, bilirubin IXα has been 
isolated by Virchow in 1847 and named by Stadeler. The first synthesis was made, and structure 
of bilirubin was solved in 1942 by a German chemist Fisher and his group, who despite the 
struggling environment of World War II made indisputably one of the biggest progressions in 
bilirubin research (462, Fisher H, Plieningher H, 1942. Synthese des biliverdins (uteroverdins) und 
bilirubins. Naturwissenschaften 30:382????). After a remarkable effort, the Fisher`s research 
methods reached their limits. Few questions remained about tautomerism, stereochemistry and 
conformation: a) The presence of a lactam or a lactim ring at the A and D ends of the bilirubin;  
b) the geometry of 5 and 15 bridges forming E or Z conformation (Pigm of life, 434). c) double or 
single bonds of C4-C5 and C15-C16  
The cutting edge work answering these questions was Bonnett`s work who used X-ray diffraction 
crystallography. His work confirmed the final structure of bilirubin as Ixα, 4Z,15Z and formation 





Figure 2 – Bilirubin structure, according to Chowdhury et al, in Disorders of bilirubin metabolism 
I.II.III. Chemical characteristics of bilirubin 
Chemical name of bilirubin is 1,8-dioxo-1,3,6,7-tetramethyl-2,8-divinylbiladiene-a,c-dipropionic 
acid. The molecule has a form of “ridge tile” which means that two from four pyrrolic rings lie in 
a different plane with the angle 98-100` in between these two planes (Figure 2,3). In both of the 
pyrroles, hydrogen bonds are between carboxylic and amino groups and lactam oxygens, 
connecting the propionic acid side chains to the opposite pyrrolic and lactam side of the 
molecule. These intramolecular bonds prevent bilirubin from interacting with polar solvents and 
are responsible for a major characteristic of bilirubin – water insolubility. This characteristic is a 
key issue in bilirubin elimination in vivo. As none of the organisms want to store its toxic products, 
the solution is in making bilirubin soluble by its conjugation with glucuronic acid.  In this reaction, 
carboxyl group of propionic acid is esterified and hydrogen bonds are disrupted. This mechanism 
is used in Van den Bergh reaction, a method using standard diazo-reaction to estimate a 
conjugated fraction of bilirubin.  Bilirubin is weakly acidic.  
Unconjugated bilirubin can form various isomers. In human body, the most abundant is the 
isomer Ixα, 4Z,15Z. Other isomers are produced as a minority. The ability of bilirubin to create 
different isomers comes from the tetrapyrrol structure of the original compound heme. The 
18 
 
isomers are formed according to the place of the cleavage of methionine bonds (Aziz, Blanckaert); 
this characteristic of bilirubin applies to the therapeutic purposes as a treatment of jaundice. 
I.II.IV. Bilirubin and light  
The effect of light on bilirubin is widely used in therapy of newborns` jaundice. Bilirubin 
undergoes photo-oxidation to form a singlet oxygen (McDonagh 1971). The light absorption is at 
450 – 474 nm. Bilirubin itself is not fluorescent, however it becomes fluorescent at 510 – 530 nm 
if dissolved in albumin solution or detergents. The principle of a phototherapy using blue light is 
a change of bilirubin conformation from Z (trans) to E (cis) with resulted bilirubin isomers in ZE, 
EE or EZ conformation. These isomers lack internal hydrogen bonds, therefore making bilirubin 
more polar and unnecessary to be conjugated with glucuronic acid.  (Mc Donagh  et al 1972,  Itoh 
et al 1985; Onishi et al 1980, Yokoyama et al 1984).  
  
Figure 3. Bilirubin 2D structure – according to 
http://pubchem.ncbi.nlm.nih.gov/compound/bilirubin 
I. II. V. Bilirubin as an antioxidant 
Bilirubin antioxidant properties have been discovered in 1987 (Stocker et al, 1987). Originally, 
the biggest bilirubin aware was because of its neurotoxic effects in newborns with non-mature 
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blood brain barrier (Criegler and Najjar 1952). This is a risk especially in infants with high bilirubin 
levels, caused by increased turnover of red blood cells as well as non-matured liver system. 
However, it was found and confirmed by numerous studies, that bilirubin is one of the strongest 
antioxidants presented in a human body. It has a scavenger effect against the free radicals 
protecting vascular cells. This means, that Gilbert`s syndrome in adults, characterized by elevated 
levels of total serum bilirubin, has a protective impact on patients with cardiovascular disorders 
such as hypertension and coronary heart disease (Wang et al, 2015).  In perspective of high 
incidence of Gilbert`s syndrome in Caucasians and current increasing incidence of lifestyle 
disorder, bilirubin plays still important role in human body homeostasis.  
I.III. Jaundice and its therapy  
Jaundice appears as a clinical sign of elevated bilirubin in adults when total bilirubin > 50 and 
mostly around 80 umol/L, therefore it is a clinical sign of several inherited hyperbilirubinemias 
(Silbertnagl et al, 2009). It is presented as a yellowish pigmentation of skin and/or sclerae. The 
most severe jaundice occurs in patients with Crigler-Najjar syndrome type I, which, without the 
early treatment, can be fatal. On the other side, in patients with Crigler-Najjar syndrome type II, 
the hyperbilirubinemia and jaundice are milder. Occasionally, jaundice is presented in Dubin-
Johnson, Rotor or Gilbert` s syndrome.   
The therapy of jaundice is well developed because of abundant incidence of jaundice in 
newborns. The pathophysiology of jaundice in newborns is different compared to inherited 
hyperbilirubinemias; it results from the rapid turnover of erythrocytes and also from the non-
mature hepatobiliary system. However, implications from the newborns therapy of jaundice have 
been adopted also for the treatment of inherited hyperbilirubinemias. As inherited 
hyperbilirubinemias are mostly mild disorders  not associated with the life-threating conditions, 
the therapy is often based on regime measurements and on avoiding certain pharmacotherapies 
(Cisplatin, Irinotecan, contraceptives). Lifestyle measurements are based on sufficient amount of 
sleep and avoiding alcohol and drugs. Dietary guidelines support healthy balanced regular diet. 
Abnormal intake of fat or imbalanced irregular sugar intake is not recommended, especially 
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because of the sugar importance in bilirubin conjugation. Also the natural-based supplements 
can have certain effect thanks to their content of flavonoids or other active substances.  
This implies to the mildest types of hereditary hyperbilirubinemia – Gilbert`s syndrome, Crigler-
Najjar syndrome II, Dubin-Johnson or Rotor syndrome. The most severe inherited 
hyperbilirubinemia – Crigler-Najjar syndrome I demands different therapy. Both, Crigler-Najjar 
syndrome I and II are mostly diagnosed within first days of newborns life (CNJ I) or during the 
childhood. The cause of both Crigler-Najjar syndromes lies in the defect of UGT1A1 gene. In case 
of CNJ II, a trace activity of the enzyme still remains and it is inducible by phenobarbital. Not so 
in CNJ I, which is a severe life-threatening condition with almost no activity of UGT1A1. CNJ I is 
characterized by excessive amount of bilirubin circulating in blood, unable to conjugate and to 
be excreted. Without therapy, the disorder has a fatal consequences. The early diagnosis is very 
critical. The blood-brain barrier of newborns is not fully maturated yet and bilirubin can cross 
from blood to the brain and because its neurotoxicity it causes kernicterus (Criegler and Najjar 
1952).  Kernicterus is serious a neonatal condition when the circulating bilirubin enters the brain 
and causes encephalopathy. It is based on bilirubin lipid solubility, able to penetrate neuronal 
and glial membranes in brain (Figure 4). Shevell et al reviews the pathologic effects of bilirubin 
penetrated to brain tissues in the most severe hyperbilirubinemia - Crigler-Najjar syndrome I.  
 
Figure 4 – kernicterus in the brain, according to 
http://neuropathology-web.org/chapter3/chapter3eBilirubinencephalopathy.html 
I.III.I. Phenobarbital therapy 
Phenobarbital has been used as a diagnostic test of Gilbert`s syndrome few years ago and it is 
not currently used in a developed countries. Phenobarbital effect on bilirubin metabolism was 
21 
 
described in seventies by several authors (Crigler et al, Catz et al). It is an inducer of hepatic 
cytochrome P450 enzyme providing faster clearance of drug metabolized by cytochrome P450. 
It is also an inducer of UGT1A1, responsible for bilirubin conjugation with glucuronic acid. 
Therefore, phenobarbital intake decreases the time necessary for bilirubin excretion in vivo 
(Crigler, Arias). The induction of UGT1A1 is currently used as a parameter of differential 
diagnostics between Crigler-Najjar syndrome I and II. Crigler-Najjar syndrome I. Therapeutic use 
of phenobarbital have been replaced by light therapy, mainly because of the lack of its side 
effects.  
I.III.II. Light therapy 
The effect of light on bilirubin has been described in detail in previous chapter. The mechanism 
of the therapy is in transformation of non-soluble unconjugated bilirubin unable to excrete, to its 
soluble form. As in most individuals with hyperbilirubinemia, the origin of the defect is in 
incapability to conjugate bilirubin in sufficient amount, light therapy enables to create easily 
soluble bilirubin isomers.  (Mc Donagh 1972,  Itoh 1985; Onishi 1980, Yokoyama 1984). 
The phototherapy as a treatment of jaundice is used since 1958. Special lamps are used to emit 
the blue visible light with the wave lengths range of 400 – 500 nm. The light cause bilirubin 
isomerization from bilirubin to lumirubin and it is further easily excreted by urine. During the 
procedure, the eyes of patients are protected by pads or by mask. Intensity of the phototherapy 
is measured by radiometer. The American Academy of Paediatrics recommends the average light 





Figure 5.  Principle of a phototherapy. According to Maisel MJ and McDonagh AD, 2008  
Several light devices are used as the light source: 
 Micro-Lite White Halogen lights 
 Fluoro-Lite - 2 Blue and 2 White Fluorescent lights 
 Fluoro-Lite - 2 Blue and 2 White Fluorescent lights 








I.IV. Excretion of coproporphyrin isomers in hereditary hyperbilirubinemia 
The heterocyclic compounds coproporphyrins are intermediates of the heme synthethic pathway 
in hematopoetic cells in liver and bone marrow. Normally, coproporphyrins are excreted as a 
products of bilirubin breakdown into the bile, feces and urine. The unusual distribution of 
coproporphyrin isomers in urine of patients with Dubin-Johnson and Rotor syndrome became 
one of the hallmark of these disorders (Koskelo et al, 1967, Mor-Cohen 2001). Yet porphyrins and 
their presence in body fluids is known for a long time, the exact mechanism of their excretion has 
not been described.  
 











I.V. UGT1A1 gene 
UGT1A1 gene (uridine diphosphate glucuronosyltransferase) is a member of a broad enzymatic 
family of uridine diphosphate glucuronosyltransferases, strongly involved in metabolism of 
xenobiotics (Bosma, 1995). These enzymes protect organism from its toxic compounds by 
glucuronidation – the addition of the glycosyl residue to the small molecule. Resulting product is 
water soluble and able to be eliminated by kidneys or by intestine. UGT1A1 mediates the 
conjugation of numerous substrates with glucuronic acid; it is the second phase of 
biotransformation of the molecules. Reaction occurs at the endoplasmic reticulum of 
hepatocytes. Following table surveys the substrates, inducers and inhibitors of UGT1A1 (adjusted 
according to www.pharmacologyweekly.com) 
Table 1 – Substrates, inducers and inhibitors of UGT1A1 
 Substrates Inducers Inhibitors 
 Acetaminophen Phenobarbital  Atazanavir 
 Atorvastatin Carbamazepine  Gemfibrozil 
 Buprenorphine  Nicotine  Indinavir 
 Carvedilol   Ketoconazole 
 Estradiol   
 Etoposide   
 Ezetimibe   
 Febuxostat   
 Fluvastatin   
 Gemfibrozil   
 Irinotecan   
 Levothyroxine   
 Losartan   
 Lovastatin   
 Ketoconazole     
 Morphine   
 Naltrexone   
 Naphthol   
 Paracetamol      
 Raloxifene   
 Raltegravir   
 Rosuvastatin   
 Simvastatin   
 SN-38   
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Genetic defects in UGT1A1 result in impaired glucuronidation and unconjugated 
hyperbilirubinemia. The most prevalent defects in a promoter region of the gene are associated 
with Gilbert`s syndrome, the rare defects in a structural part of the gene result in Crigler-Najjar 
syndrome type II or in a most severe hereditary hyperbilirubinemia – Crigler-Najjar syndrome 
type I.   
I.VI. Gilbert`s syndrome 
The defect in UGT1A1 gene results in inherited hyperbilirubinemia, Gilbert´s syndrome (GS) 
(OMIM ID:143 500). GS is a hereditary, chronic, mild, benign, unconjugated hyperbilirubinemia 
resulting from impaired bilirubin clearance with otherwise normal liver function. The degree of 
hyperbilirubinemia is relatively mild, mostly less than 80 μmol/L (4.7 mg/dL) in adults (Bosma et 
al, 1995). Considerable daily and seasonal variations are observed, and bilirubin levels 
occasionally may be normal in as many as one third of patients. Icterus is mild, usually limited to 
sclerae and mucosae. Typically, bilirubinemia is enhanced following hunger, strenuous physical 
exercise, surgery, stress, or fever. Patients may report general discomfort or fatigue. The animal 
model to study Gilbert`s syndrome is Gunn rat.  
Genetic variants associated with GS 
Gilbert´s syndrome is linked to the mutations in uridine diphosphate glucuronosyltransferase 
(UGT) 1A1 gene located on chromosome 2q37 with autosomal recessive inheritance. In 
Caucasians, the frequency of GS is 5–10% (Owens and Evans, 1975). The most common variant is 
the TA insertion in the TATAA box of the UGT1A1 called UGT1A*28 or 
NG_002601.2:g.[175492_175493insTA]. Wild type A(TA)6TAA is replaced by A(TA)7TAA allele; 
the variant is prevalent in a Caucasians with the frequency of 11-16% in homozygous state 
(Bosma et al, 1995, Owens and Evans 1975). The other non-pathogenic variant, also  presented  
in  promoter region of UGT1A1, is  c.-3279T>G (rs4124874), located in phenobarbital enhancer 
responsive module upstream of  TATAA box of the gene. This variant also results in decreased 
glucuronidation and impaired excretion of bilirubin. Both variants, c.-3279T>G and UGT1A*28 
are tightly linked (Maruo et al, 2004, Jirsa et al, 2006) Other types of mutations in Gilbert´s 
syndrome are primarily missense mutations, which are rare in Caucasians but common in Asians. 
UGT1A1 protein preferentially binds and conjugates bilirubin in hepatocytes thereby eliminating 
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products of heme breakdown. The activity of the enzyme is about 30% of the normal level in 
patients with Gilbert´s syndrome (Bosma et al, 1995, Takeuchi et al, 2004). 
 
I.VII. Crigler-Najjar syndrome I 
The most severe inherited hyperbilirubinemia is Crigler-Najjar syndrome I  (CNJ I) (OMIM 218 
800) with the total serum bilirubin around 340-685 µmol/L or higher. The syndrome was firstly 
described by Crigler and Najjar in 1952. Hyperbilirubinemia is obvious since early days of 
newborn life with no significant decrease after phenobarbital administration. This is caused by 
the mutations in the structural part of UGT1A1 gene, leading to almost absent activity of UGT1A1 
enzyme. Since the UGT1A1 is the only enzyme catalyzing conjugation of glucuronic acid with 
bilirubin, the defect has serious life threating consequences and immediate treatment is 
necessary. The only long-term treatment is in liver transplant (Ciotti et al, 1997). The inheritance 
of CNJ I is autosomal recessive (Chowdhury et al, 2001). Interestingly, four cases of a rare CNJ I 
were found among Slovakian Roma population (Zmetakova et al, 2007). 
 
I.VIII. Crigler-Najjar syndrome II 
As well as Crigler-Najjar syndrome type I, CNJ II is also caused by the genetic defects in the 
structural part of UGT1A1 gene. Unlike CNJ I, in CNJ II the activity of mutated UGT1A1 is > 10 %, 
which enables its inducibility. The hyperbilirubinemia is from 60-340 µmol/L (Crigler and Najjar, 
1952, Arias et al, 1969). Also phototherapy has a better perspective. Most of the defects are 
substitutions in UGT1A1 gene, inherited autosomal recessively, however also autosomal 
dominant model of CNJ II was detected (Koiwai et al, 1996, Bosma et al, 1995) The differentiation 
between CNJ I and CNJ II is possible by phenobarbital test, molecular genetic analyses and clinical 
history.  
 
I. IX. ABCC2 gene 
The link between the ABCC2 gene and hereditary jaundice was discovered by Paulusma and 
Elferink group in 1996, the scientists exploring the congenital jaundice in TR- rats. Previously, 
ABCC2, furtherly named cMOAT, was discovered at cisplatin-resistant tumor cells and cloned by 
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Taniguchi and by Buchler the same year. (Taniguchi et al 1996, Buchler et al, 1996). The gene is 
located at human chromosome 10q24 chr10:99782732-99852192 (hg19). The Genomic structure 
of ABCC2 was described by Toh et al (Toh et al, 1999). ABCC2 spans 32 exons and exhibits high 
similarity to ABCC1 and ABCC3.  
Although the association of ABCC2 and Dubin-Johnson syndrome was predicted by Zimniak 
already in 1993, the first mutations were found by Wada`s team five years later. Up to today, 
more than 40 mutations in ABCC2 causing Dubin-Johnson syndrome have been discovered (see 
table). Moreover, a rare dual hereditary hyperbilirubinemia was found as a result of defect in two 
genes - ABCC2 and UGT1A1 (Cebecauerova et al, Slachtova et al 2015). However, more attention 
than mutations in ABCC2 attracted the often prevalent SNPs in ABCC2, known as the significant 
influencers of drug elimination. 
Table 2. Mutations found in ABCC2 gene, May 2015 
Mutation Effect Reference 
   
c.821_822delCT  Devgun (2012) Ann Clin Biochem 49, 609 
c.974C>G p.S325* Corpechot (2006) Am J Gastroenterol 101,2427 
c.998A>G p.D333G Arlanov (2012) Hum Mutat 33, 750 
c.1013_1014delTG p.V338Efs14*        Slachtova (2015) Eur J Hum Genet 
c.1031+4A>G  Mor Cohen (2005) Hepatol Res 31, 104 
c.1135C>A p.Q379K Devgun (2012) Ann Clin Biochem 49, 609 
c.1177C>T p.R393W 
Machida (2005) J Gastroenterol 40, 366, 
Lee (2006) Pediatr Res 59: 584  
c.1234A>G p.R412G Hulot (2005) Pharmacogenet Genomics 15,277 
c.1249G>A p.V417I 
Meyer zu Schwabedissen (2005) Drug Metab Dispos 33, 896, 
Megaraj (2011) Pharmacogenet Genomics 21: 506 
Deo (2012) Drug Metab Dispos 40: 852  
c.1256_1272delins17  Cebecauerova (2005) Gastroenterology 129, 315 
c.1321C>A p.L441M Lee (2006) Pediatr Res 59, 584 
c.1815+2T>A  Wada (1998) Hum Mol Genet 7, 203 
c.1967+2T>C  Kajihara (1998) Biochem Biophys Res Commun 253, 454 
c.2026G>C p.G676R Wakusawa (2003) J Hum Genet 48, 425 
c.2125T>C p.W709R 
Machida (2004) Hepatol Res 30, 86, 
Uchiumi (2012) Hepatol Res 
c.2302C>T p.R768W 
Wada (1998) Hum Mol Genet 7, 203, 
Hashimoto (2002) Hepatology 36: 1236  
c.2360_2366delCCCTGTC Sticova (2013) World J Gastroenterol 19, 946 
c.2366C>T p.S789F 
Hirouchi (2004) Pharm Res 21, 742, 




Wada (1998) Hum Mol Genet 7, 203, 
Toh (1999) Am J Hum Genet 64: 739  
c.298C>T p.R100* Shoda (2003) Hepatol Res 27, 322 
c.3196C>T p.R1066* Paulusma (1997) Hepatology 25, 1539 
c.3258+1G>A  Sticova (2013) World J Gastroenterol 19, 946 
c.3399_3400delTT  Lee (2006) Pediatr Res 59, 584 
c.3449G>A p.R1150H Mor-Cohen (2001) J Biol Chem 276, 36923 
c.3517A>T p.I1173F Mor-Cohen (2001) J Biol Chem 276, 36923 
c.3521G>A p.R1174H Arlanov (2012) Hum Mutat 33, 750 
c.3542G>T p.R1181L Arlanov (2012) Hum Mutat 33, 750 
c.3563T>A p.V1188E 
Floreani (2006) Hepatology 43, 1152, 
Sookoian (2009) J Nutr Biochem 20: 765  
c.3732T>G p.N1244K Arlanov (2012) Hum Mutat 33, 750 
c.3817A>G p.T1273A 
Corpechot (2006) Am J Gastroenterol 101,2427, 
1000 Genomes Project (2010) Nature 467: 1061  
c.3825C>G p.Y1275* Lee (2006) Pediatr Res 59, 584 
c.3872C>T p.P1291L Arlanov (2012) Hum Mutat 33, 750 
c.3928C>T p.R1310* Tate (2002) Genes Genet Syst 77, 117 
c.3972C>T p.I1324I 
Sookoian (2008) J sHepatol 48, 125, 
Benz-de Bretagne (2011) J Biomed Biotechnol 2011: 498757 
c.4054G>C p.E1352Q Lee (2006) Pediatr Res 59, 584 
c.4145A>G p.Q1382R 
Toh (1999) Am J Hum Genet 64, 739, 
Hashimoto (2002) Hepatology 36: 1236  
c.4175_4180delGGATGA  Tsujii (1999) Gastroenterology 117, 653 
c.4292_4293delCA  Cebecauerova (2005) Gastroenterology 129, 315 
c.4348G>A p.A1450T 
Hirouchi (2004) Pharm Res 21, 742, 
Megaraj (2011) Pharmacogenet Genomics 21: 506 
c.4430C>T p.T1477M Megaraj (2011) Pharmacogenet Genomics 21,506 
c.4544G>A p.C1515Y 
Elens (2011) Pharmacogenet Genomics 21,884, 
Sookoian (2009) J Nutr Biochem 20: 765 
 
I.IX.I. Non-pathologenic variants in ABCC2 gene  
The biggest interest in ABCC2 and its variants is related to its drug-metabolizing function. 
Functional SNPs in ABCC2 as well as in other transporters (ABCB1, ABCB2) have been investigated 
for their modulatory effect on mrp2 expression or other association with anti-cancer therapy 
such as tamoxifen, cisplatin etc (Schwabedisser et al 2005, Dai et al,2008, Kiyotani et al 2010) or 
with antiepileptic drugs, carbamazepine or valproate (Hung et al 2012)  
I.IX.II. Expression of ABCC2 
ABC transporters play an important role in biotransformation of various organic anions and 
elimination of toxic compounds from the organism. The largest, ABCC subfamily has 13 
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transporters, most of them involved in active transport of xenobiotics and other metabolic 
products. ABCC2 or MRP2 is a 190 kDa transmembrane protein expressed on many tissue 
barriers, apical membrane of polarized cells. In vertebrates it is hepatocytes, enterocytes, renal 
proximal tubules, placenta, or in endothelial cells of blood-brain barrier. The expression is 
regulated by several chemical or biological agents such as drugs (phenobarbital, glucocorticoids), 
by transcription regulators (Nrf2), or by disease conditions such as cholestasis or in the presence 
of a tumor (Wang et al, 2014, Payen et al, 2002). 
MRP2 protein is highly conserved and occurs in protozoa, bacteria, plants or, vertebrates. AA 
conservation within the species (orthologs). The amino acid identity between MRP2 and its 
paralog MRP1 is not high ~ 48%, but the substrate specificity is surprisingly similar for both of the 






















I.IX.II. Molecular characteristics of MRP2 
Cellular localization of MRP2 corresponds to its function as the ATP transporter. Achored in 
cytoplasmic membrane, MRP2 exports and imports various substrates using energy from ATP 
hydrolysis. The protein has 1545 amino acids, three membrane spanning domains, a linker and 
two nucleotide binding domains (NBD).  In nucleotide binding domain, ABC transporterss have  
the specific motifs with a consensus sequence is called Walker motifs, specifically Walker motif 
A, B, and C. These motifs are highly conserved and MRP2 has all of them (Taniguchi et al,1996). 
Transmembrane domains MSD1 and 2 consists of six transmembrane helixes. Compared to the 
other ABC proteins forming only two membrane spanning domains (MSD1, MSD2), MRP2 has 
one more MSD located at NH2- end of the protein. This MSD0 is important for  targeting and 
anchoring  to the apical membrane (Hipfner 1997). The other end of the protein, the C-terminal 
part, contains a  PDZ-binding domain, critical for the apical sorting of the protein (Nies et al, 
2002).   
The mechanism of substrate transport suppose the existence of two binding sites – one for the 
substrate and the other one for regulating the affinity by allosteric regulation (Zelceret al,  2003). 
To enable transport, tight cooperation of both units is necessary.  
Crystal structure of ABC transporters, thanks to their high impact on human life, has been studied 
with a tremendous effort and interest. Since the transporters have several domains, and are 
anchored in a plasma membrane, it was not easy to obtain the structural information at all. Up 
until today, the only crystal structure of MRP2 was obtained from trypanosoma brucei in a 
complex with MRP1 and guide RNA by Schumacher et al (Schumacher, et al 2006).  
I. IX.III. Post translational modification of MRP2  
Post translational modifications of proteins (PTM)  are reactions based on the covalent addition 
of functional group to the proteins after translation and they play an important role in cell 
signaling. Several PTMs are known for MRP2 – glycosylation and ubiquitination. Cells are using 
the ubiquitination in a process of elimination of disrupted proteins by marking the protein by 
ubiquitin and by then adding ubiquitins next. Ubiquitinated protein is recognized and targeted to 
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proteasome for further destruction. Ubiquitination in MRP2 has been described in rats and also 
in cell culture by Hayashi and Aido.  
I.IX.IV. Mrp2 and drug resistance 
The first instance of multidrug resistance of ABC protein was made already in 1976 by Juliano, 
observing P-glycoprotein abundantly expressed in Chinese hamster ovary drug-resistant cells. 
The exo- and endogenous ATP-dependent anionic pump protects organisms from the toxic 
compounds of their catabolism across the cell membrane, transporting mainly conjugates with 
glucoronate, glutathione, sulphate or amphiphilic anions. This life-protecting function of the cell 
and organism on the other hand has become the serious obstacle in pharmacotherapy. Multidrug 
resistance is implicated in numerous failures of cancer treatment, in resistance to antibiotics or 
herbicide resistance in plants (Holland et al). 
Due to the severe consequences of multidrug resistance, a great effort has been developed to 
eliminate MRPs function during cancer treatment; and for such a purpose,  four generations of 
MRP modulators have already been created (Coley et al). MRP2 modulators supposedly work by 
stimulating or inhibiting two MRP2 binding sites – ones the substrate binding site or the other – 
affinity modulating site. However, each modulator interacts with MRP2 and substrate specifically 
depending on the substrate (Zelcer  et al, 2003). 
I.IX.V. Animal models  
The first animal model considered as the alternative of Dubin-Johnson syndrome in humans was 
Corriedale sheep, characterized by the pigmented liver and disturbed excretion of 
coproporphyrins (Cornelius et al, 1965). TR- rat strain, also called Groningen Yellow, was 
developed as the next animal model and led to the discovery of the connection between Dubin-
Johnson and MRP2 and further enabled functional characteristic of MRP2. TR- rats have a 
deletion in g.1179.Also Eisai rats, the other model of DJS, derived from Sprague-Dawley  and 
Wistar rats, are still used these days. Eisai rats have a mutation in ABCC2 resulting in a stop codon. 
A rare model of DJS, a golden lion tamarin monkey is characterized by conjugated 
hyperbilirubinemia and bromosulfophthalein retention; it is not currently used for DJS studies 
(Schulman et al).  
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I.IX.VI. In vitro system  
Systems in vitro has been developed mainly to study and characterize the transporter`s function 
and substrate binding on cellular level. Compared to animal models, in vitro experiments use 
transport vesicles as well as cell cultures; these models enable fast and affordable experiments. 
In early studies of bile and glucuronide transport, the liver plasma membrane vesicles were used, 
but for the studying the substrate and sole transporters itself the model wasn`t sufficient. Liver 
plasma membrane vesicles contain a lot of ABC transporters, therefore a more specific system 
was necessary. Cell lines provided the adequate technology for this purpose and they are used 
for studying MRP2 up until today – HEK 293, MDCK II. Another favourable model to study drug 
elimination, transporters and substrate specificity is primary hepatocytes, which –compared to 
transport vesicles and cell lines – provides the natural system for ABC transporters, preserving 
their natural environment (Guofeng).   
I.X. Dubin-Johnson syndrome  
As the inherited hyperbilirubinemia, Dubin-Johnson syndrome (OMIM 237 500) was firstly 
described by Dubin and Johnson and coincidentally by Sprinz and Nelson in 1954. Thanks to the 
similarity of disturbances in coproporphyrin isomers excretion, one period of time it was thought 
that DJS is one of the other metabolic disorders – porphyrias (Kadish, 1999), resulting from the 
defect of uroporphyrin co-synthetase. However, this enzyme has been found linked to congenital 
erythropoetic porphyria and the pathways of both proteins were found totally separate. 
DJS is a rare recessively inherited form of conjugated hyperbilirubinemia. It is caused by the 
homozygous or compound heterozygous mutations in ABCC2 gene. Genetic disturbance results 
in a defected protein responsible for mediating the transport of bilirubin glucuronides and other 
endogenous substances out of the hepatocytes.  
I.X.I. Clinical and laboratory characteristics of DJS 
Laboratory tests do not show elevated transferases or alkaline phosphatase in DJS patients. 
Clinically, several patients have vague symptoms of abdominal pain or fatigue, and depending on 
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the bilirubin level, jaundice can occur. There is no pharmacotherapy necessary. There are several 
clinical signs of DJS with no other liver pathology: 
 1/ Increased conjugated bilirubin in blood and a mild elevation of total bilirubin (Kadish for total) 
The reference range for conjugated bilirubin in blood of healthy individuals is < 4 umol/L, patients 
with DJS show cBi > 4 umol/L. This effect is caused by inability of hepatocytes to transfer 
conjugated bilirubin into the bile, normally mediated by MRP2. When MRP2 is mutated, bilirubin, 
instead of going to the bile to be further metabolised in the intestine, mostly returns back to the 
blood stream. 
 2/Disturbed pattern of coproporphyrin isomers excretion in urine with predominance of 
coproporphyrin I (Koskelo 1967, Ben-Ezzer 1971). Physiologically, there are 2 isomers of 
coproporphyrin excreted to the urine of healthy adults: coproporphyrin I and coproporphyrin III. 
In humans, Isomer III occurs as the product of the heme degradation. In healthy adults, the ratio 
is 70-80% of coproporphyrin III compared to 20-30% of excreted coproporphyrin III in patients 
with DJS. Heterozygotes carrying one mutated copy of ABCC2 and one healthy allele are excreting 
mostly around 40-60% of coproporphyrin III. The excretion of coproporphyrins also varies in 
newborns, where the hepatobiliary system is not yet matured. The mechanism of inverted 
excretion of coproporphyrin isomers has not been described yet, however it is clear that there is 
some connection with MRP2, which is also expressed at epithelial cells of kidneys proximal tubuli. 
Before the era of molecular genetics the analysis of coproporphyrin isomers have been the major 
laboratory tool to distinguish between homozygotes DJS and heterozygous carriers.  
3/ Delayed excretion of sulfobromophtalein (BSP) or 99mTc-HIDA in bile tract. 
Shani et al described delayed retention of sulfobromopthalein in DJS patients. Plasma BSP has 
been observed to be higher in 90 minutes after injection compared to 45 minutes. Again, this 
effect of delayed excretion of BSP organic anion is caused by the defect or absent MRP2, so the 
conjugates are returned to the blood stream. The same principle has also been documented on 
the administration of bilirubin IXa to the patients with DJS or, with the excretion of (64)Cu-5 in 
TR- rats (Yoo). The experiment using BSP is not used anymore however for the visualization of 
gallbladder and bile ductus is mostly used 99mTc-HIDA, developed by Bar-Meir et al. transitions  
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4/pigmentation of liver  
A pigment presented in lysosomes of hepatocytes in patients with DJS is found by a liver 
histology.  The pigment has been characterised as a melanin like pigment containing lipofuscin, 
also presented in DJS animal model – a Corriedale sheep (Cornelius C, 1965). Experiments with 
diet of TR- rats, the other model of DJS, showed, that liver pigmentation develops when diet is 
rich on aromatic amino acids, suggesting the clearance of their metabolites by MRP2 (Kitamura 
T) . Except the pigmentation, liver physiology remains intact. However, pigmentation hallmark of 
DJS is not found in all of the patients with DJS.  
I.X.II. Population genetics of DJS 
As all hyperbilirubinemias except Gilbert`s syndrome, Dubin-Johnson syndrome is a rare disorder. 
The higher prevalence of recessively inherited Dubin-Johnson syndrome is linked to the isolated 
populations. Such populations are often characterized by the common place of origin, cultural, 
historical, religion or social attributes. The impact resulting from the enclosed populations is loss 
of natural genetic variability within the generations and higher occurrence of recessively 
inherited disorders, such as Dubin-Johnson or Rotor syndrome. According to literature, DJS is 
highly prevalent in Iranian (1:20, mutation I1173), Moroccan (frequency of carriers 1:100, 
R1150H) or Ashkenazi Jews (Mor Cohen et al, 2005). Founder effect was discovered in a 
population of Slovakian Roma according our study and confirmed by haplotyping (Slachtova et 
al, 2015). 
I.XI. Rotor syndrome 
Recently discovered Rotor syndrome (RS, OMIM 237 450) is a conjugated type of inherited 
hyperbiblirubinemia, caused by a defects in two genes encoding transport proteins. The 
association of OATP1B1 and OATP1B3 with Rotor syndrome was found by Steeg et al in 2012 
(Steeg et al, 2012). Both proteins are ATP dependent pumps, responsible for transport of organic 
anions on the membrane of hepatocytes.  Conjugated hyperbilirubinemia is mild, the excretion 
of coproporphyrin isomers is switched as well as in Dubin-Johnson syndrome. However, the 
excretion of coproporphyrin isomer I is ~ 60% compared to 80 – 90 % as it is in DJS. The bile tract 
























The aims of the study were to characterize the molecular pathology of hereditary 
hyperbilirubinemias in Caucasian and Roma population and to compare the clinical and 
biochemical results with the molecular genetic data.  
 
1. To find the coincidence of c.-3279T>G variant in PBREM of UGT1A1 and UGT1A*28 allele 
with TA insertion in TATAA box and its impact on serum bilirubin levels in probands with 
Gilbert`s syndrome and in healthy controls  
 
2. To characterize the Dubin-Johnson syndrome on both molecular genetic and biochemical 
levels; To perform a mutation analysis of ABCC2 in patients with DJS and its effect on 
bilirubin elimination 
 
3. To study the excretion of coproporphyrin isomers in patients with DJS and its comparison 
with the genetic defect in ABCC2 
 



































We tested following hypotheses: 
1. Coincidence of c.-3279T>G variant in PBREM of UGT1A1 and UGT1A*28 allele with TA 
insertion in TATAA box impact on serum bilirubin levels in probands with Gilbert`s 
syndrome. Based on the functional studies of c.-3279T>G variant we suppose that the 
presence of both genetic defects in UGT1A1 results in increased level of total serum 
bilirubin.  
 
2. Patients with Dubin-Johnson syndrome have elevated conjugated bilirubin in blood; 
hyperbilirubinemia depends on the size of damage of ABCC2 protein.  
 
3. Excretion of coproporphyrin isomers reflects the genetic disturbances in ABCC2, resulting 
in elevated isomer I in urine samples of the patients with DJS. Excretion is dependent on 
genetic background of the defect and on environmental factors of xenobiotic elimination. 
 
4. Patients with Dual hereditary jaundice, a coincidental defect in both ABCC2 and UGT1A1 
genes have different patterns of bilirubin elimination compared to a single defect in 
patients with DJS. We expect that patients with Dual hereditary jaundice have decreased 

































IV.I. Study ethics and informed consent 
According to Czech law, all genetic studies carried out have to be approved by responding Ethic 
and Medical Committee. Informed consent, provided by the subjects included to the studies, has 
two main purposes. Once, it is in both patient`s interest to obtain sufficient information in 
advance to any medical procedure, including the blood testing and more importantly, DNA 
analyses. Secondly, the act is legally documented as the act of the free will by the assignment of 
three participating subjects (individual or his/her legal representative, the healthcare 
professional and a witness). All the studies hereto described were held after the proper education 
of investigated subjects, and the studies were approved by the Committee of Medical Ethics at 
the First Faculty of Medicine, Charles University and General Faculty Hospital in Prague.   
IV.II. Patients 
All individuals enrolled to the studies were Caucasians from Czech or Slovak Republic. In the first 
study, the patients and controls from the study #1 were adolescents from Department of 
Pediatrics, First School of Medicine, Charles University and General Faculty Hospital in Prague. In 
the second study, patients and their family members were enrolled by clinical genetics based on 
the signs of hereditary hyperbilirubinemia. All patients and family members from study #2 are 
Roma origin living in Slovak Republic.  
IV.III. Measurement of bilirubin 
In all patients and in most of the family members the standard biochemical liver tests (ALT, AST, 
total and conjugated serum bilirubin) were performed from 7ml anticolaguant blood sample. 
Bilirubin was measured by a photometry based on diazo reaction developed by van den Bergh 
using Ehrlich` s reagent. The measurement was carried on automatized analyzers (Beckman 






IV.IV. Coproporphyrin isomers` analysis 
Coproporphyrine isomers were measured from the urine samples of 8 patients with hereditary 
hyperbilirubinemia (study  #2). For each measurement, 100 mL of urine per patient was taken 
and stored in a dark at -80C and further separated by HPLC. HPLC instrument (GE Healthcare) 
was equipped by a fluorescence detector, allowing excitation at 405 nm and emission at 620 nm. 
The column and precolumn cartridge used for separation of was from Chromsystems (44100, 
18044). Buffers used for the analysis were Mobile Phase A and B from the same manufacturer 
(#44001, #44002). Coproporphyrin isomers were separated using commercially available kit 
Porphyrins in Urine (# 44000, Chromsystems).  
IV.V. Molecular genetic analyses 
For DNA analyses, 2,5 mL (for infants, children) or 7 mL of whole blood in EDTA were taken. DNA 
was extracted from peripheral leukocytes using standard desalting method or Qiagen QIAamp 
DNA Blood Minikit (Qiagen, Hilden, Germany), following the manufacturer`s protocol. DNA was 
eluted in water and stored in 4°C for a long term use. For DNA analyses, DNA was further diluted 
for working concentration 1-20 ng/uL. Primers used for amplification were designed, with 
exception of primers for c.-3279T>G, described previously (Sugatani et al, 2002). 
IV.V.I Gene UGT1A1 and surrounding region 
 TA insertion in UGT1A1 gene 
HGVS names: NG_6002601.2:g.175492_93 [insTA]  
           rs8175347  
           UGT1A*28 
We have investigated the most important variant causing GS in UGT1A1, UGT1A*28. Initially, the 
key region - the TATA box of UGT1A1 gene was sequenced (Slachtova et al, 2009). Even when 
we`ved experienced high quality results by sequencing, we`ve switched to a less time consuming 
and cheaper method using fluorescent labeled primers – a fragment analysis. For the sequencing 
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analysis we used the primer with the same sequence but no labeling. For fragment analysis, the 
primers were labeled using 6FAM dye.  
TATAA box of UGT1A1   
Primer Sequence Product Tm 
TATA F 6FAM-AACTCCCTGCTACCTTTGTGG 
231/243 60˚C 
TATA R TCCAACAGTATCTTCCCAGCATGGG 
 
PCR MIX                        PCR Program   
 uL  1.       95˚C/2 min   
PP Mix 6,25  2.       95˚C/30 sec   
H2O 4,95  3.       62˚C/40 sec   
Primer forward + reverse 2,5 
pmoL 0,4 + 0,4  
4.       72˚C/30 sec 
  
DNA 50 ng/ul 0,5  5.       Go to step 2, repeat steps 2-4/25x 
Total 12,2  6.       72˚C/30 sec   
 
 Variant in phenobarbital enhancer module c.-3279T>G  
HGVS names: chr2:hg19:g172270T>G 
           rs4124874 
PBREM enhancer variant was assessed with RFLP described previously (Sugatani et al,  2002) The 
method use DNA amplification by PCR and following digestion using restriction enzyme. After the 
PCR product is digested, the products with a different length are separated on 2% agar gel 






IV.V.II.  ABCC2 Gene 
In second study, all 56 individuals were investigated for a genetic defect in ABCC2 gene. In 
probands, all 32 exons and adjacent intron regions of ABCC2 gene were investigated. Exons were 
numbered according to Ref. Seq. NG_011798.1. Proband`s DNA was amplified using PCR, PP 
Master Mix polymerase with buffer (Top-Bio) and 2.5 pM of primer (see table). Amplified 
products were purified using Promega A9282 kit and sequenced with 3.2 pM primer by ABI PRISM 
3100 AVANT (Applied Biosystems, Big Dye Terminator 3.1 Sequencing Kit). Unlike probands, all 
healthy family members or carriers were investigated only for a causal disease-causing variant in 
exon eight. 
PCR MIX                        PCR Program 
 uL  1.       95˚C/2 min 
PP Mix 6,25  2.       95˚C/30 sec 
H2O 4,95  3.       Tm˚C/40 sec 
Primer forward + reverse 2,5 
pmoL 0,4 + 0,4  
4.       72˚C/30 sec 
DNA 50 ng/ul 0,5  5.       Go to step 2, repeat steps 2-4/30x 
Total 12,2  6.       72˚C/30 sec 
 
Primers    

















































































































IV.V.III. Microarray on Genome Wide Human SNP 6.0 
To receive a large-scale data for the haplotyping, we used the Affymetrix Genome Wide Human 
SNP Array, 6.0 featuring about 1.8 milion genetic markers. The chip carries more than 906 600 of 
SNP probes  with a minor allele frequency > 5 % and over 946 000 of copy number variations.  
The amount used for genotyping on Affymetrix GWH SNP 6.0, for measurement of concentration 
and for electrophoresis was 1 ug with a concentration > 50 ng/ul). In advance of hybridization, 
we checked the quality of our samples to meet the critical criteria for the analysis. 40 samples 
met the quality control check and continued for further analyses. The hybridization process 
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includes following steps: 1/ DNA digestion with restriction enzyme StyI, 2/ligation to an adaptor 
with T4 DNA ligase, 3/PCR of the template with TITANIUM Taq DNA polymerase, 4/ Digestion 
with NsP restriction enzyme, 5/ Ligation with Nsp, 6/ PCR reaction, 7/ purification of PCR product, 
8/ quantification, 9/fragmentation with DNAse, 10/ end-labeling with terminal deoxynucleotidyl 
transferase and 11/ hybridization of the target.  
Genotype calling and quality check control 
After the hybridization of DNA to the probes, the data were evaluated with use of Affymetrix 
Genotyping Console version 4.1. The loss of heterozygosity (LOH) was determined with the same 
software (Supplementary Figure 1). LOH is a method using a data from the hybridized probes 
(SNPs, CNVs) to indicate a genetic changes resulting from the loss of variability within the 
chromosome. It is mostly used in the cancer genomics where it shows the absence of 
heterozygosity in cancer cells, but it is also a tool for a detection of recessive disorders.  
Haplotyping 
The genotyping data were entered into PLINK 1.07 and SNPs on chromosome 10 were selected 
for a further analyses. Unphased genotype data of the whole cohort were entered into the 
Genotype Visualization and Algorithmic Tool (GEVALT) software, version 2. Phasing, linkage 
disequilibrium (LD) analysis and estimation of the haplotype block structure was performed 
utilizing the Genotype Resolution and Block Identification with Likehood (GERBILT) algorithm. A 
haplotype block of 21 SNPs encompassing the site of c.1013_1014delTG variant in ABCC2 gene 
was selected to include following SNPs rs2756115, rs17112219, rs3184991, rs2093354, 
rs2804412, rs2804409, rs2756095, rs717620, rs4919395, rs2756103, rs4148389, rs4148389, 
rs17222744, rs2804398, rs2756109, rs11816875, rs2804397, rs2273697, rs2002042, rs4148396, 
rs4148399, rs7476245. The age of the ancestral variant c.1013_1014delTG in Slovakian Roma 
population was estimated using a standard Luria - Delbrück algorithm modified by Austerlitz in 
Mathematica 8 using the Mathematica notebook provided by F. Austerlitz. Variant`s age was 




IV. V. IV. Statistical analyses 
Statistical analyses of the first study used calculation of ODDs ratio and linkage disequlibrium 
analyses. Regular statistical calculations we used in our studies were average, standard deviation 
or elementary quantification calculations.  
IV.V.V. Linkage disequilibrium (D) 
The calculation of linkage disequilibrium used in the first study describes a non-random 
association of two alleles in a chromosome locus/loci and reflect the DNA recombination in a 
population. For the calculation is necessary to know the frequency of each allele in the sample, 
which is determined by  
 
p1 = x11 + x12 for allele A1 
p2 = x21 + x22 for allele A2 
q1 = x11 + x12 for allele B1 
q2 = x12 + x22 for allele B2 
 
Linkage disequlibrium D = x11 = p1q1 
Linkage disequlibrium is presented when both loci and alleles are independent from each other 
and its denoted by D≠ 0. The maximum of D is reached when allelic frequencies are 0,5. genetic, 
the D is mostly calculated together with its normalized level D`  
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Dual hereditary jaundice – a combination of Dubin-Johnson and Gilbert´s syndromes, is a rare 
clinical entity resulting from the compound defects of bilirubin conjugation and transport. We 
aimed to study the hereditary jaundice in 56 members from seven seemingly unrelated Roma 
families, to find the causal genetic defect and to estimate its origin in Roma population. Based on 
biochemical results of total and conjugated serum bilirubin and clinical observations, ABCC2 
gene, TATA box and phenobarbital enhancer (PBREM) of UGT1A1 gene were analysed by 
sequencing, RFLP and fragment analysis. We found a novel variant c.1013_1014delTG in the 
eighth exon of ABCC2 gene in 17 individuals in homozygous state. Dual defect 
NG_011798.1:c.[1013_1014delTG]; NG_002601.2:g.[175492_175493insTA] in homozygous state 
was found in four subjects. Biochemical analyses of porphyrins and coproporphyrin isomers in 
urine performed by HPLC showed inverted ratio of excreted coproporphyrin, with the 
predominance of coproporphyrin I (up to 100 %), typical for patients with Dubin-Johnson 
syndrome. Pursuant cultural and social specifics of the population led us to suspect a founder 
effect; therefore we performed a haplotype study using genotyping data from Affymetrix 
Genome-Wide Human SNP Array 6.0. As a result, we detected a common 86 kbp haplotype 
encompassing promoter and part of the ABCC2 coding region among all families, and estimated 
the age of the ancestral variant to 178-185 years. In this study, we found a novel deletion in 
ABCC2 gene, described genetic and biochemical features of dual hereditary jaundice and 




Keywords: bilirubin, Dubin-Johnson syndrome, Gilbert´s syndrome, ABCC2, UGT1A1, 
coproporphyrin, Roma population, rare diseases 
INTRODUCTION 
Bilirubin excretion involves bilirubin conjugation with glucuronic acid (mediated via uridine 
diphosphate glucuronosyltransferase 1A1 - UGT1A1) followed by the transport of bilirubin 
conjugates from hepatocytes into the bile by MRP2 (multidrug resistance-associated protein 2, 
coded for by ABCC2 gene). Genetic defects in bilirubin elimination pathway clinically manifested 
by jaundice are known as hereditary hyperbilirubinemias. Dubin-Johnson syndrome (DJS; OMIM 
#237500) is a rare autosomal recessive hyperbilirubinemia characterized by the absence of 
functional MRP2 protein at the canalicular membrane of hepatocytes.1-4 MRP2 protects 
organisms from the toxic compounds of their catabolism and its intact function is a pitfall in 
anticancer therapy.5-6 To date, more than 40 variants in ABCC2 causing DJS have been described 
(Human Genome Mutation Database) and several SNPs with pharmacogenomics importance. 7,8 
The clinical profile of DJS comprises of:   (1) Conjugated hyperbilirubinemia in blood (> 7 µmol/L), 
(2) inverted ratio of excreted coproporphyrin isomers I to III in urine (> 80 % of isomer I), (3) 
prolonged visualization of liver by technetium (Tc-99)-labeled hepatobiliary iminodiacetic acid 
99mTc-HIDA and, (4) abnormal deposits of melanin-like pigment in lysosomes of hepatocytes. Liver 
function remains otherwise normal.9 The rare DJS is highly prevalent among small populations in 
Iranian (1:20), Moroccan (frequency of carriers 1:100), or Ashkenazi Jews (www.health.gov.il). 
3,10 Such a founder effect reflects the deviation from the natural selection and the population 
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isolation, potentiated by consanguineous marriages, resulting in a loss of genetic variability over 
generations. 
Gilbert` s syndrome (GS; OMIM #143500) is relatively common among the general population. 
The frequency of TA insertion in TATA box (rs8175347) of UGT1A1 gene (Ref. Seq. NG_002601.2) 
in Caucasians is around 30 %, with the 5 % manifestation by jaundice.11 Reduced transcription of 
UGT1A1 gene with 7 TA repeats (NG_002601.2:g.[175492_175493insTA]) compared to wild type 
6 TA repeats. The reduction is often potentiated by simultaneous presence of variant c.-3279T>G 
(rs4124874) in PBREM, located in a promoter region of UGT1A1. Finally, it results in lower 
glucuronidation causing unconjugated hyperbilirubinemia with the total serum bilirubin > 20 
µmol/L and usually < 80 µmol/L.12,13 
Dual hereditary jaundice, a compound d`efect of bilirubin conjugation (GS) and transport (DJS), 
was firstly described by Cebecauerova et al.14 Biochemical characteristics of dual hereditary 
jaundice correspond to predominant defect of bilirubin glucuronides transport, including 
conjugated and total bilirubin elevation and urinary coproporphyrin isomer I increase as 
mentioned above.  
The population of Roma (Gypsies) is the largest minority in Europe of about 11 millions of 
individuals. A great majority of European Roma shares the same haplotypes - haplogroup H-M82 
of chromosome Y and mitochondrial haplogroup M. Their common ancestors originate 1500 
years ago from Northern India.15-17 
In this work, we investigated the prevalence of dual hereditary jaundice among 56 members from 
seven seemingly unrelated Roma families.  Here, we report the identification of a novel variant 
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in ABCC2 gene together with a compound defect in ABCC2 and UGT1A1 genes and a shared 
haplotype among all seven families. These findings demonstrate the highest prevalence of DJS in 
Europe thus far. Moreover, this is the first study to describe biochemical and molecular genetic 
defects of bilirubin transport and coproporphyrin excretion in several individuals with dual 
hereditary jaundice. 
 
PATIENTS AND METHODS 
Patients. A total of 56 individuals from 7 unrelated Slovak Roma families were investigated for 
suspected hereditary hyperbilirubinemia. All participants signed the informed consent approved 
by the Ethics Committee of General University Hospital in Prague. The first proband was a girl 
from a large family with a history of noninfection jaundice, born from a consanguineous marriage 
of two cousins (Figure 1). Her biochemical tests showed total bilirubin (TBi) of 35-70 µmol/L, 
conjugated bilirubin (cBi) of 31-54 µmol/L (F 1.IV/17) and normal levels of alanine 
aminotransferase - ALT, and aspartate aminotransferase - AST. She was hospitalized at the age 
of nine months due to the severe bilirubinemia, acute respiratory infection and suspected anemia 
and treated with Unasyn, Dithiaden, Halixol, folic acid, Maltofer and glucose. The performed 
99mTc-HIDA cholescintigraphy of liver and biliary tract revealed delayed visualization of liver and 
gallbladder, typical for Dubin-Johnson syndrome. Similarly, other individuals were tested for TBi 
and cBi (standard diazo- reaction), ALT and AST.  
Genetic analyses. Genomic DNA was extracted from 7 mL whole blood in EDTA using standard 
procedures. All 32 exons and adjacent intron regions of ABCC2 gene (NM_000392.4, exons were 
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numbered according Ref. Seq. NG_011798.1, Supplementary Table 1) were amplified using PCR, 
PP Master Mix polymerase with buffer (Top-Bio, Prague, Czech Republic) and 2.5 pM of primer; 
purified (Promega A9282 kit); and sequenced by ABI PRISM 3100 AVANT (Applied Biosystems, 
Big Dye Terminator 3.1 Sequencing Kit). Fragment analysis of TA insertion of TATA box of UGT1A1 
gene was performed (rs8175347, chr2:hg19:g.175492_175493insTA)   (see Supplementary 
Table 1). PBREM enhancer variant c.-3279T>G (rs4124874; chr2:hg19:g.172270T>G) was 
amplified and assessed with RFLP as described previously. 12 All sequence variants were 
annotated according to reference sequences (NG_011798.1 for ABCC2, NG_002601.2 for 
UGT1A1), and the findings were submitted to ClinVar database 
(http://www.ncbi.nlm.nih.gov/clinvar). 
Coproporphyrin isomers analysis. Urine samples from 8 patients with jaundice were collected 
(100 mL per patient), and stored in dark at -80°C. Porphyrins and coproporphyrin isomers I and 
III were analyzed by HPLC with a fluorescence detector (excitation 405 nm, emission 620 nm), 
Chromsystems column (# 44100) and kit Porphyrins in Urine (# 44000, Chromsystems).  
Microarray, haplotyping and variant´s age estimation. To assess a common haplotype, genomic 
DNA from 40 individuals was hybridized to Affymetrix Genome Wide Human SNP Array 6.0 
according to manufacturer´s recommendation and further analysed. Genotype calling and loss of 
heterozygosity in 10q24 region was determined with Affymetrix Genotyping Console version 4.1. 
The genotyping data were entered in PLINK 1.07 18 and SNPs present on chromosome 10 were 
selected for further analyses. After performing standard quality checks, unphased genotype data 
of the whole cohort were entered into the Genotype Visualization and Algorithmic Tool (GEVALT) 
software, version 2.19 Phasing, linkage disequilibrium (LD) analysis and estimation of the 
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haplotype block structure was done utilizing the Genotype Resolution and Block Identification 
using Likehood (GERBILT) algorithm.20 A haplotype block encompassing the site of 
c.1013_1014delTG variant in ABCC2 gene included 21 SNPs. The age of the ancestral variant 
c.1013_1014delTG in Slovakian Roma population was estimated using a standard Luria - Delbrück 
algorithm modified by Austerlitz 21 in Mathematica 8 using the Mathematica notebook kindly 
provided by F. Austerlitz. Variant`s age was estimated for a current population size of 400 000 – 
450 000 Roma.22 
 
RESULTS 
Biochemical blood tests included total and conjugated serum bilirubin, ALT and AST. ALT and AST 
ranged within normal levels, indicating the absence of liver damage. TBi in DJS patients was 18.8 
- 72.2 µmol/L with cBi 9.5 - 55.2 µmol/L (Table 1). The percentage of cBi out of TBi in patients 
with dual defect DJS + GS were 28 %, 38 %, 43 % and 89 % (see Table 2). The last value 89 % was 
found in proband F1.IV/17 on medication with following TBi/cBi: 38/33; 70/55; and 35/31 
µmol/L.  Values of TBi and cBi of patients with the same UGT1A1 and ABCC2 haplotype varied 
(Table 1). 
Molecular genetic analysis of the proband revealed the deletion in ABCC2 gene 
c.1013_1014delTG (http://www.ncbi.nlm.nih.gov/clinvar/?term=SCV000195771), responsible 
for Dubin-Johnson syndrome (Figure 1). The causal variant is located in the eighth exon and, via 
a frameshift, it leads to a premature stop codon p.(Val338Glufs14*) resulting in a shortened 
protein product. Investigation of TATA box of UGT1A1 of the same proband showed also 
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NG_002601.2:g.[175492_175493insTA]  causing  Gilbert´s syndrome.  Next, family members and 
probands were investigated for the defect in ABCC2 gene with the total result of 17 homozygous 
patients with the deletion c.1013_1014delTG and 30 heterozygous carriers as evident from 
Figure 1. The presence of the same genetic defect in all seven seemingly unrelated families 
suggested a founder effect of c.1013_1014delTG among the investigated Roma families. 
Moreover, four patients with homozygous variant in ABCC2 gene were also homozygous for the 
TA insertion in TATA box of UGT1A1 gene with a genotype 
NG_011798.1:c.[1013_1014delTG]; NG_002601.2:g.[175492_175493insTA] (Table 1). All 
patients with homozygous TA insertion were also homozygotes for   c.-3279T>G variant in PBREM 
(Table 1 and Supplementary Table 2).  
Pedigrees from seven investigated families are depicted onFigure 1. Consanguineous marriages 
between cousins were found in three of them (F 1, 4, 5). In five families, both parents were 
heterozygous carriers of variant c.1013_1014delTG. In next two families, fathers´ samples were 
not available, however the genotypes of offspring suggest heterozygous or homozygous 
occurrence of the mutated allele in both fathers.  
Coproporphyrin isomers excretion. We analyzed coproporphyrin isomers in urine samples of 11 
individuals: in eight patients with DJS caused by c.1013_1014delTG in ABCC2 gene and in three 
heterozygous carriers. Significantly increased proportion of excreted coproporphyrin isomer I 
was observed in all DJS patients with values ranging from 89-100 % (Table 2).  In heterozygous 
carriers, the ratio of excreted isomer I was 43-57 %, compared to about 25-30 % in healthy 
controls (control data from literature).23,24 No differences were found in excrection of 
coproporphyrin isomers in patients with DJS compared to thouse with dual defect of DJS + GS.  
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Microarrays and haplotyping. The analysis of chromosome 10 genotypes in ABCC2 region 
revealed a shared 86 kbp haplotype upstream and within ABCC2 gene, transmitted together with 
the deletion c.1013_1014delTG (Figure 2, Table 3). Furthermore, the loss of heterozygosity was 
found in all homozygous patients with DJS with use of CNV analysis from Affymetrix Genotyping 
Console. Loss of heterozygosity in DJS patients was in all cases in concordance with both genetic 
and biochemical data.   
Estimation of variant´s age. Age of ancestral variant c.1013_1014delTG was estimated using the 
Luria-Delbrück algorithm modified by Austerlitz.20,21 Population size of Slovakian Roma 
inhabitants was set at 400 000 – 450 000 22 and the frequency of disease allele was estimated 
between 0.01 – 0.001.  Using these data, our results show that the variant originated 7.1-7.4 
generations ago, which corresponds to 177.5 – 185 years ago (Supplementary Table 3).   
DISCUSSION 
Our study describes compound defect of ABCC2 and UGT1A genes, causing Dubin-Johnson and 
Gilbert`s syndrome. The frequency of TA insertion in UGT1A1 in Caucasians is about 15 %.25 
Similar distribution may be assumed in the Roma population, although the accurate frequency 
has not been established yet. The new variant c.1013_1014delTG described herein is located in 
the eighth exon of ABCC2 gene. A two base pair deletion leads to frameshift and truncation of 
the encoded MRP2 protein, from original size of 1545 amino acids to the reduced size of 352 
residues. Deletion truncates protein´s two of total three membrane spanning domains (MSD2 
and MSD3) and one ATP binding site, and newly formed mRNA probably subjects to a rapid 
degradation.4 The excretion of conjugated bilirubin into the bile is performed mainly via ABCC2 
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efflux pump with minor elimination via ABCG2.26,27 However, ABCG2 does not provide sufficient 
substitution of impaired ABCC2, and bilirubin glucuronides are transported by upregulated 
basolateral MRP3 into the blood. 
Biochemistry. Results of total bilirubin and its conjugated fraction correspond to 
presence/absence of genetic defect in bilirubin pathway (Table 1). All DJS patients with 
homozygous presence of c.1013_1014delTG had elevated cBi (9-55 µmol/L) as well as TBi (19-
72 µmol/L). Both TBi and cBi showed high variability within the same genotype. Fluctuating 
bilirubin levels are present in both - DJS and GS. Many factors affecting hyperbilirubinemia have 
been described, with the most important TA insertion, found in four our patients with DJS and in 
two healthy DJS carriers.  
Effect of a double defect. To date, dual hereditary jaundice has been described only in a single 
case by Czech authors Cebecauerova et al. with no additional studies up today. 15 Our study 
describes the coincidental defects in two genes of bilirubin metabolism in another four patients. 
The percentages of cBi out of TBi in our DJS + GS patients were 28 %, 38 %, 43 % and 89 %, 
respectively (Table 1). We suppose, that coincidental defects of bilirubin conjugation and 
transport result in decreased amount of cBi available for its transport, therefore the percentage 
of cBi from TBi is < 50 % in DJS + GS compared to > 50 % in DJS only (Table 1, Supplementary 
Table 2). Except the last value of 89 % (baby girl proband, data collected under medication), our 
findings are in agreement with the previous study. Both proteins UGT1A1 and MRP2 are 
responsible for the drug`s biotransformation, which may explain a higher cBi and TBi in patient 
with dual defect under medication. Certain drug precautions should be taken in advance of 
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pharmacotherapy in patients with dual hereditary jaundice including irinotecan, atazanavir, 
cisplatin, vincristine or doxorubicin to prevent its toxicity or sensitivity. 28,29,  
Coproporphyrin. Urinary excretion of coproporphyrin reflects the heme degradation and 
excreted isomers are presented as isomers I – IV with the most significant isomers I and III. The 
proportion of coproporphyrin isomer III in urine samples of healthy adults is 70-80 %, compared 
to ~ 20-30 % in DJS patients, who excrete about 80-97 % of coproporphyrin I. Under normal 
conditions, excretion of coproporphyrin isomers depends on maturation of hepatobiliary system 
and changes within the first days of newborn’s life.30,31 
We have investigated coproporphyrin in 8 patients with DJS caused by c.1013_1014delTG in 
ABCC2 and all of them showed shifted ratio excreted coproporphyrin isomers in urine (89-100 %, 
Table 2). Several studies show > 90 % predominance of coproporphyrin I in urine of patients with 
DJS, but to our knowledge, no data show results of 100 %. 32,33  Our patient with 100% excretion 
of isomer I was one year old boy with total serum bilirubin 50 µmol/L and its conjugated fraction 
21 µmol/L. Coproporphyrin isomers were analysed from two independent samples with the same 
result. Before the era of molecular genetics, heterozygous carriers of DJS were only detectable 
by changed isomers of coproporphyrin in urine. Compared to 20-30 % in healthy controls, 
heterozygotes secrete about 40 % of isomer I. Average percentage of isomer I in our DJS carriers 
was 43-57 %, which is similar to data from literature.23,24,35 Excretion pattern of coproporphyrin 
isomers in four patients with dual hereditary jaundice was the same as in other DJS patients with 
no defect in UGT1A1 (see Table 2). Our findings for coproporphyrin I was 92, 97, 99 and 100 % in 
patients with dual defect compared to 89, 93, 96 and 98 % in DJS patients with heterozygous 
NG_002601.2:g.175492_175493insTA and 89 % in DJS patient with the wild type UGT1A gene.  
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Haplotyping and dating an ancestral variant. After the finding an identical genetic defect, we 
have suspected the founder effect of c.1013_1014delTG variant among Roma families. The 
consanguinity was observed in 3 of 7 families and all families lived within tens of kilometres of 
one another (Supplementary Figure 1). We have identified a common haplotype spanning 86 kbp 
segregating with the deletion in ABCC2 and a loss of heterozygosity in ABCC2 region in patients 
with DJS (Figure 2). Several haplotype analyses of ABCC2 had been performed due to its 
pharmacogenomic impact, even one concerning the impact of ABCC2 haplotype on 
coproporphyrin excretion, but only using SNPs with proven pharmacogenomics effect.36,37 There 
are more than 130 SNPs within ABCC2 and their importance in vitro has mostly not been 
described yet. Our study clearly shows, that in addition to the ABCC2 haplotype, which is shared 
in our DJS patients, other factors may also influence coproporphyrin excretion in urine, such as 
SNPs in other genes or undiscovered environmental factors.  
Dating the ancestral variant c.1013_1014delTG in Slovakian Roma population revealed the 
probable origin of variant 178 – 185 years ago. Allelic association estimates the age of the 
ancestral variant from haplotypic data, without specification of the population growth rate.21 
 
Conclusion 
Our study describes defects in UGT1A1 and ABCC2 genes corroborating genetic findings with 
biochemical results in more individuals with dual hereditary jaundice.   In 17 Roma patients with 
DJS we have detected a new deletion NG_011798.1:c.[1013_1014delTG], which represents the 
highest prevalence of DJS in Europe. Four of our patients were homozygous for a dual defect 
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NG_011798.1:c.[1013_1014delTG]; NG_002601.2:g.[175492_175493insTA]. We also uncovered 
the existence of the founder effect of ABCC2 variant in all patients from seven families and a 
shared haplotype 86 kbp and estimated the age of the deletion to 178 – 185 years.  
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Tables (attached) 
Table 1 Total and conjugated bilirubin (in µmol/L) and genotype of patients with/out Dubin-
Johnson1 and Gilbert´s2 syndrome. Legend 1 +/+ homozygote for c.1013_1014delTG in ABCC2; 2 
6/6 healthy, 6/7 heterozygote, 7/7 homozygote for g.175492_175493insTA in UGT1A1; bold - 
double homozygotes 
Table 2 Excretion of coproporphyrin isomers I and III in urine and serum bilirubin in patients with 
Dubin-Johnson (+/+) and Gilbert´s syndrome (7/7) and in healthy carriers (+/-) or (6/7) 







S Table 1 Primers and PCR conditions 
S Table 2 Total and conjugated bilirubin (in µmol/L) and genotypes of heterozygotes and 
healthy individuals. Legend DJS -/- healthy; +/- heterozygote; +/+ homozygote for 
c.1013_1014delTG in ABCC2;   GS 6/6 healthy, 6/7 heterozygote, 7/7 homozygote for 
g.175492_175493insTA in UGT1A1 
S Table 3 Estimation of age of deletion c.1013_1014delTG in ABCC2 in Slovakian Roma 
S Figure 1 Map of the Slovakia with indicated occurrence of founder effect of 
c.1013_1014delTG in ABCC2 
Titles and legends to figures 
Figure 1a Sequences of deletion in ABCC2 c.1013_1014delTG (Ref Seq NG_011798.1; 
NM_000392.4) 1. homozygous variant c.1013_1014delTG in patient with DJS                    2. 
heterozygous variant in carrier 3. wild type 
Figure 1b  Pedigree of the families with  Dubin-Johnson syndrome       homozygote, 
    Heterozygote,    healthy,    male,    female,    unknown – abortion; N – not investigated; arrow 
– proband; double bond  indicates consanguinity;  
Figure 2 The span of a common haplotype in families with DJS encompassing c.1013_1014delTG  
in ABCC2 gene with indication of linkage disequilibrium (r2). Black diamonds without numerical 
annotation correspond to complete linkage disequilibrium between the SNPs. Only polymorphic 
SNPs are shown. 
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Figure 1a      
 




















Family Genealogy DJS1 GS2 PBREM cBi Tbi % cBi of Tbi  
F1 
II/2 -/- 6/6 T/T 1.9 5.7 33.3  
II/3 +/+ 6/7 T/G 28.7 46.5 61.7  
II/5 +/+ 6/7 T/G 55.2 72.2 76.5  
II/6 -/- 6/7 T/G 2.3 7.6 30.3  
III/1 -/- 6/7 T/G 1.8 3.6 50.0  
III/2 +/- 6/7 T/G 2.0 12.3 16.3  
III/3 -/- 6/6 T/T 0.1 4.6 2.2  
III/4 +/- 6/7 T/G 2.8 7.2 38.9  
III/5 +/- 6/6 T/T 2.3 6.5 35.4  
III/6 +/- 6/7 T/T 1.8 5.1 35.3  
III/7 +/- 6/6 T/T 1.0 2.8 35.7  
III/8 -/- 6/6 T/T 2.4 9.5 25.3  
III/9 +/- 6/7 T/G 0.3 9.0 3.3  
III/10 +/- 6/7 T/G 1.2 1.5 80.0  
III/11 +/- 6/6 T/T 0.7 5.7 12.3  
III/12 +/- 6/6 T/T 0.2 3.7 5.4  
III/13 +/- 6/7 T/G 0.3 5.0 6.0  
III/14 +/- 6/7 T/G 0.2 5.5 3.6  
IV/1 +/- 7/7 G/G 1.5 6.8 22.1  
IV/2 -/- 6/7 T/G 3.0 3.8 78.9  
IV/3 +/- 6/6 T/T 0.2 4.7 4.3  
IV/4 +/- 6/7 T/G - - -  
IV/5 +/- 6/7 T/G - - -  
IV/6 +/- 6/7 G/T - - -  
IV/7 +/- 6/7 T/G - - -  
IV/8 +/- 6/7 T/G 1.8 5.8 31.0  
IV/9 +/- 6/7 T/G - - -  
IV/10 -/- 6/7 T/G 3.0 5.5 54.5  
IV/11 -/- 6/7 T/G - - -  
IV/12 +/+ 6/6 T/T 16.7 28.1 59.4  
IV/13 +/+ 7/7 G/G 17.7 46.7 37.9  
IV/14 +/- 6/6 T/T 1.3 4.5 28.9  
IV/15 +/- 6/7 T/G 3.2 12.7 25.2  
IV/16 +/+ 6/7 T/G 9.5 18.8 50.5  
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IV/17 +/+ 7/7 G/G 31.0 35.0 89.0  
Family Genealogy DJS1 GS2 PBREM cBi Tbi % cBi of Tbi  
F2 
I/1 +/- 7/7 G/G - - -  
I/2 +/- 6/7 T/G - - -  
 
II/1 +/+ 6/7 T/G 11.4 32.4 35.2  
II/5 +/+ 7/7 G/G 16.9 60.4 28.0  
F3 
I/1 +/- 6/7 T/G - - -  
I/2 +/- 6/7 T/G - - -  
II/1 +/+ 7/7 G/G 21.4 49.5 43.2  
II/2 +/+ 6/6 T/T - - -  
F4 
I/1 +/- 6/7 G/G - - -  
I/2 +/- 6/7 G/G - - -  
II/1 +/+ 6/6 T/G 28.0 42.0 66.7  
II/2 -/- 6/7 T/G - - -  
F5 
I/1 +/+ 6/6 T/G 32.7 39.9 82.0  
I/2 +/- 6/7 T/G - - -  
II/1 +/+ 6/7 T/G - - -  
F6 
I/1 +/- 6/6 T/T - - -  
II/1 +/+ 6/7 T/G - - -  
II/3 +/+ 6/7 T/G 17.6 43.5 40.5  
F7 
I/2 +/- 6/6 T/G - - -  
II/2 +/+ 6/6 T/T 32.4 57.4 56.4  
II/6 +/+ 6/6 T/T - - -  















                        
  F1.IV/13 F1.IV/17 F2.II/5 F3.II/1 F1.II/5 F1.IV/16 F2.II/1 F3.I/1 F4.I/1 F4.I/2 F4.II/1  
Total 
porphyrins  
212 348 258 78 587 230 205 91 93 58 133 
 
[nmol/L]                        
Uroporphyrin 88 80 78 13 118 74 84 10 6 6 19  
[nmol/L]                        
Coproporphyrin 124 268 180 63 469 156 121 78 75 52 110  
[nmol/L]                        
Isomer I (%) 99 97 92 100 98 96 93 43 53 57 89  
Isomer III (%) 1 3 8 - 2 4 7 57 47 43 11  
Conjug. 
bilirubin  
17.7 31.0 16.9 21.4 55.2 9.5 11.4 - - - 28.0 
 
[µmol/L]                        
Total bilirubin 46.7 35.0 60.4 49.5 72.2 18.8 32.4 - - - 42.0  
[µmol/L]                        
DJS +/+ +/+ +/+ +/+ +/+ +/+ +/+ +/- +/- +/- +/+  
GS 7/7 7/7 7/7 7/7 6/7 6/7 6/7 6/7 6/7 6/7 6/6  
             
Ref. ranges: Total porphyrins <300 nmol/L;  uroporphyrin < 40 nmol/L; coproporphyrin <150 nmol/L; 
                        Conjug. Bilirubin < 7 µmol/L, total bilirubin < 20 µmol/L     


















 I/1  I/2 II/1  II/5  
 father mother daughter son 
rs2756115 T C T C C C C C 
rs17112219 G G G G G G G G 
rs3184991 T T T T T T T T 
rs2093354 A A A A A A A A 
rs2804412 G G G G G G G G 
rs2804409 T T T T T T T T 
rs2756095 A A A A A A A A 
rs7176201 C C C C C C C C 
rs4919395 G A G A A A A A 
rs2756103 A C A C C C C C 
rs4148389 A G A G G G G G 
rs17222744 A A A A A A A A 
rs2804398 A T A T T T T T 
rs2756109 T T T T T T T T 
rs11816875 G G G G G G G G 
rs2804397 G G G G G G G G 
c.1013_1014delTG W * W * * * * * 
rs2273697 A G A G G G G G 
rs2002042 C C C C C C C C 
rs4148396 C T C T T T T T 
rs4148399 T G T G G G G G 


















































VI.I. Aim 1, Paper 1 - Does Bilirubin Level Correspond to Interaction of c.-3279T>G and 
A(TA)7TAA Variants in UGT1A1 Gene? 
Functional studies show, that promoter variant c.-3279T>G, as well as A(TA)7TAA decrease the 
transcription of UGT1A1 up to 60 %, resulting in consequently reduced  glucuronidation of 
bilirubin and affecting its elimination as a toxic product (Bosma et al, 1995, Sugatani et al, 2002). 
Therefore, coincidence of both variants should lead to significant increase of hyperbilirubinemia.  
Combined genetic defect affecting glucuronidation of bilirubin and its elimination was described 
on the compound defects of A(TA)7TAA and other variants, located in a coding region of  UGT1A1 
(Kamisako, 2004).  
In our cohort of 101 patients and 84 controls from general Caucasian population we have studied 
the impact of coincidental occurrence of both genetic defect located in promoter region of 
UGT1A1 on serum bilirubin and calculated the linkage disequlibrium of both variants.  It is 
important to highlight, that presented data are describing genetic defects in Caucasian 
population. In Japanese population, the prevalent variant causing Gilbert`s syndrome is G211A 
(Koiwai et al, 1995).  
The frequency of [(TA)7] allele in healthy controls was 32%, which responds to the data from 
literature (Bosma et al, 1995, Jirsa et al, 2006, Kabicek 2007). Regarding c.-3279T>G variant, 
frequency of this variant was 39% among healthy population. As expected, significantly higher 
incidence of both variants was found in patients with GS – 99 % carried variant c.-3279T>G variant 
and 97 % had [(TA)7] allele. The linkage between both variants in controls was D´= 0.79, r2 = 0.47 
compared to linkage in patients with GS D´ = 1, but r2was very low (0.32). The ODDs ratio of c.-
3279T>G variant and Gilbert`s syndrome was OR 34.42, confirming the strong association of 
PBREM promoter variant and GS.   
The linkage of c.-3279T>G and A(TA)7TAA in promoter region of UGT1A1 was previously 
suggested by Maruo et al (Maruo et al, 2004), who postulated the hypothesis, that the presence 
of both variants is necessary for the manifestation of Gilbert`s syndrome. However, next study 
conducted by Czech authors Jirsa et al on a larger cohort showed, that even when the linkage of 
both variant is strong, it is not necessary for clinical manifestation of GS (Jirsa et al, 2006). 
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The effect of both promoter variants c.-3279T>G and A(TA)7TAA in UGT1A1 on serum bilirubin is 
summarized in Table 2 (Slachtova et al, 2009). 
 T/T   T/G   G/G 
6/6  8,37 (±2,31)  8,47 (±0,81)  13 
6/7  8,48 (±3,66)  10,58 (±4,39)  13,62 (±3,15) 
7/7  0   12,3 (±4,53)  0 
 
With the development of molecular genetic techniques, current data confirm the importance of 
various genetic defects on glucuronidation or bilirubin elimination. Several studies based on 
haplotyping techniques show the importance of genotyping variants involved in glucuronidation 
and elimination of toxic compounds. Bilirubin is transformed into its soluble form solely by 
UGT1A1. However, importance of haplotyping  doesn`t involve the elimination of only bilirubin, 
but especially the clearance of other toxic compounds as the UGTs are the general drug 
metabolizing enzymes (Lankisch 2009).  
VI.II. Aim 2 – Paper 2 - To characterize the Dubin-Johnson syndrome on both molecular genetic 
and biochemical levels; To perform a mutation analysis of ABCC2 in patients with DJS and its 
effect on bilirubin elimination.  
In literature, DJS has been characterized in a cohort of 101 Israeli patients, collecting biochemical, 
clinical and family history data (Shani et al, 1970). However, there is no study describing the 
defects on molecular genetic data, the relationship of mutations in ABCC2, impact of the mutated 
protein on direct excretion of bilirubin or coproporphyrin isomers.  
Our study describes the biochemical and molecular genetics relationship on 56 investigated 
members from 7 Slovakian Roma families, which is the largest cohort described in Europe up 
today. Our data suggest the common ancestral mutation allele with the origin of 178-185 years 
ago. In the beginning of our study, we hoped to obtain more variable cohort with various 
mutations, analyse the impact of the protein damage on cellular level and compared the data 
within the cohort. However, when analysing our data, we found, that the high incidence of rare 
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Dubin-Johnson syndrome is caused by the effect of one founder mutation, and that all probands 
share the common haplotype of 86 kbp encompassing ABCC2 gene. According the Table…, and 
in concordance with literature, conjugated bilirubin is presented in all DJS patients with 
homozygous presence of c.1013_1014delTG had elevated cBi (9-55 µmol/L) as well as TBi (19-
72 µmol/L).  (Slachtova et al, 2015, Dubin and Johnson, 1952); however it is clear that the bilirubin 
levels are fluctuating even within the same haplotype, suggesting that bilirubin elimination does 
not reflect only the genotype, but also the influence of environmental factor, age of the probands 
or nutrition.   
 
VI. III – Aim 3 and 4 – Paper 2 To study the excretion of coproporphyrin isomers in patients with 
DJS and to compare it with the genetic defect in ABCC2;  to describe genetic and biochemical 
characteristics of Dual hereditary jaundice 
 Coproporphyrin isomers in urine are excreted as isomers I – IV with the most significant isomers 
I and III. In healthy adults, the proportion of coproporphyrin isomer III in urine is ~ 70-80 %, 
compared to ~ 20-30 % in DJS patients, who excrete about 80-97 % of coproporphyrin I. Under 
normal conditions, excretion of coproporphyrin isomers depends on maturation of hepatobiliary 
system and changes within the first days of newborn’s life (Koskelo et al, Kondo et al 1976). 
In our study, we have investigated coproporphyrin isomers in 8 patients with DJS caused by 
c.1013_1014delTG in ABCC2 and all of them showed shifted ratio excreted coproporphyrin 
isomers in urine (89-100 %, Table 2). Several studies show up to > 90 % predominance of 
coproporphyrin I in urine of patients with DJS, but no data shows results of 100 % (Ben Ezzer et 
al, 1973, Shani et al, 1970). Our patient with 100% excretion of isomer I was one year old boy 
with total serum bilirubin 50 µmol/L and its conjugated fraction 21 µmol/L. Coproporphyrin 
isomers were analysed from two independent samples with the same result. Unafected 
heterozygotes secrete about 40% of isomer I compared to 20-30 % of isomer I in healthy controls. 
Average percentage of isomer I in our DJS carriers was 43-57 %, which is in concordance with a 
data from literature. Surprisingly, excretion pattern of coproporphyrin isomers in four patients 
with dual hereditary jaundice was the same as in other DJS patients with no defect in UGT1A1 
Patients with dual defect of NG_011798.1:c.[1013_1014delTG]; NM_000463.2:c.[-54_-53insTA] 
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had the ratio of  coproporphyrin I 92, 97, 99 and 100 % , compared to 89, 93, 96 and 98 % in DJS 
patients with only heterozygous NG_002601.2:g.175492_175493insTA and 89 % in DJS patient 
with the wild type UGT1A gene. This data suggest, that the excretion of coproporphyrin isomers 
depends not only on genotype of the patients but also on the other factors.  
Dual hereditary jaundice has been described in a single case by other Czech authors. Our study 
aimed to collect more data on this rare condition, affecting both conjugation and transport of 
the bilirubin. In our study we are describing four DJS + GS patients. Supposed effect on the ratio 
of conjugated and excreted bilirubin is decreased amount of cBi available for its transport; 
therefore the percentage of cBi from TBi is < 50 % in DJS + GS compared to > 50 % in DJS only. 
We found a ratio of conjugated bilirubin fraction of 28 %, 38 %, 43 % and 89 %. The last value of 
89 % is from a probands whose data were collected under medication, probably affecting the 






































Inherited hyperbilirubinemias are the metabolic disorders, mostly manifested in children; 
therefore their early diagnosis and adequate therapy is of great interest. Currently, there are 
known all genes responsible for the protein defects, resulting in an increased levels of bilirubin 
circulated in a blood stream. However, thanks to the rarity of some of hyperbilirubinemias, the 
estimation of the diagnosis still may take years. The importance of the knowledge of such a 
disorder is especially in avoiding certain pharmacotherapy, whose effect may change a mild 
condition to a life threating consequences. During other studies, we would like to highlight 
several recommendation: 
 early molecular diagnosis testing should be taken into account already in non-typical 
jaundice of newborns 
 the molecular genetics testing should consider the population specifics and medical 
history should already include this information 
 as all of the proteins associated with inherited hyperbilirubinemias are also very 
important entities in biotransformation of toxic compounds and drug metabolizing 
enzymes, molecular genetic testing should be regularly performed before indication 
specific pharmacotherapy. Namely in a treatment of oncologic patients or in young 
adolescents taking hormonal contraceptives.  
 genetic counselling in enclosed population with the risk of founder effect mutations about 
the increased risk of transmission of recessive disorders in consanguineous marriages.  
 
Genetic and biochemical part of our study of inherited hyperbilirubinemias raised following 
questions to be study: 
 what factors, except the genetic ones are affecting the excretion of coproporphyrin 
isomers? 
 what is the cause of inverted ratio of excreted coproporphyrin isomers in patients with 
DJS and RS? 
 in case of Dubin-Johnson syndrome, what is the importance of localization of the 
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